药物治疗老年高血压对hs-CRP和ICAM-1水平的影响

目的：通过比较老年原发性高血压患者使用瑞舒伐他汀治疗前后的情况,探讨瑞舒伐他汀对老年原发性高血压患者血清超敏C反应蛋白（hs-CRP）和细胞间黏附分子-1（ICAM-1）水平的影响。方法：选取86例老年高血压患者随机分为对照组和治疗组,其中对照组进行采用氨氯地平治疗,而治疗组在对照组的基础上采用瑞舒伐他汀治疗,分别检测和比较两组患者的hs-CRP和ICAM-1水平,并进行统计学分析。结果：与治疗前相比,治疗后对照组与治疗组hs-CRP和ICAM-1均明显降低,而两组的hs-CRP和ICAM-1差异显著（t=3.1655,P〈0.01;t=9.6983,P〈0.01）,具有统计学意义。结论：瑞舒伐他汀能显著降低老年高血压患者的hs-CRP和ICAM-1水平,减轻患者的炎性反应,具有重要的临床应用价值。

Effect of Rosuvastatin on High-Sensitive C-reactive Protein and Intercellular Adhesion Molecule-1 in Elderly Patients with Primary Hypertension

Objective： By comparing the situation about elderly patients with primary hypertension before and after using rosuvastatin, we investigated its comfortable felling statin on serum hypersensitive c-reactive protein（hs-CRP） in elderly patients with primary hypertension and intercellular adhesion molecule 1（ICAM- 1） the influence of the level. Methods： 86 patients with primary hypertension were randomly divided into control group and treatment group. The control group were treated with amlpdipine, and the treatment group were treated with rosuvastain and amlpdipine. The levels of hs-CRP and ICAM-1 were analyzed. Results： After treatment, the levels of hs-CRP and ICAM-1 of both groups were decreased, but comparing with control group, hs-CRP and ICAM-1 in treatment group have the signification difference（t=3.1655, P〈0.01; t=9.6983, P〈0.01）. Conclusion： Rosuvastatin which can reduce the levels of hs-CRP and ICAM-1 and the inflammatory reaction in elderly patients with primary hypertension has important clinical value.